Department of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Indian J Pediatr. 2019 Jun;86(6):548-550. doi: 10.1007/s12098-019-02895-7. Epub 2019 Feb 13.
Intestinal failure-associated liver disease (IFALD) is a fatal complication of short bowel syndrome managed with parenteral nutrition. A clinical cohort study reported the usefulness of parenteral administration of fish-derived omega-3 fatty acids in improving IFALD; however, no biomarker has been developed as yet. The authors report the case of a preterm infant with IFALD complicated by extensive short bowel syndrome. Intravenous administration of omega-3 fatty acids were introduced using Omegaven®at the age of 4 mo for IFALD. The IFALD improved with an increase in Eicosapentaenoic acid (EPA)/ Arachidonic acid (AA) ratio (from 0.08 to 1.99) 7 d after the intravenous treatment. It is important to administer omega-3 fatty acids intravenously at an early stage for IFALD associated with extensive short bowel syndrome. A low EPA/AA ratio may be a serum marker of disease activity in IFALD.
肠衰竭相关肝病（IFALD）是短肠综合征患者接受肠外营养治疗的致命并发症。一项临床队列研究报告了经肠外给予鱼源 ω-3 脂肪酸在改善 IFALD 方面的有效性；然而，目前尚未开发出生物标志物。作者报告了一例因广泛短肠综合征而并发 IFALD 的早产儿病例。该患儿在 4 月龄时因 IFALD 而开始使用 Omegaven®经静脉给予 ω-3 脂肪酸。在静脉治疗 7 天后，二十碳五烯酸（EPA）/花生四烯酸（AA）比值（从 0.08 增加到 1.99）升高，IFALD 得到改善。对于与广泛短肠综合征相关的 IFALD，早期进行 ω-3 脂肪酸静脉给药很重要。低 EPA/AA 比值可能是 IFALD 疾病活动的血清标志物。
